Chongqing Lummy Pharmaceutical Co Ltd

Chongqing Lummy Pharmaceutical Co Ltd has a current liquidity position that is characterized by a debt-to-equity ratio of 0.21 and a current ratio of 2.09, indicating a moderate level of liquidity risk. The company reported negative net cash after subtracting total debt, which is a key liquidity flag. Free cash flow for the period was negative at -125,411,190 CNY, while operating cash flow was positive at 26,037,760 CNY. The company's profitability metrics are weak, with a return on equity of -7.67% and a return on assets of -5.23%. These figures are below the typical performance of the pharmaceutical industry, which is expected to maintain positive returns on equity and assets. The company reported a net loss of 134,705,330 CNY and an operating loss of 146,169,090 CNY, indicating a significant underperformance in its core operations. Geographically, the company's revenue is concentrated in the domestic Chinese market, with no disclosed international operations. The company operates in a single business segment, which is typical for smaller pharmaceutical firms in China. However, the lack of diversification increases exposure to domestic regulatory and economic risks. The company's growth trajectory is mixed. Revenue for the period was 775,686,200 CNY, but the company reported a net loss. Analysts have recorded the last actual revenue at 775,686,200 CNY and an EPS of -0.13 CNY. The company's capital expenditures were -38,155,050 CNY, suggesting a reduction in investment in new projects or facilities. The company faces several risk factors, including liquidity concerns and a weak profitability position. The risk assessment indicates a medium level of liquidity risk and a low level of dilution risk. The company has not disclosed any recent share issuance or dilution events, and the number of shares outstanding has remained unchanged. Recent events include the company's financial performance, which has been marked by a net loss and a decline in operating income. The company has not disclosed any major regulatory or legal issues, but the pharmaceutical industry in China is subject to frequent regulatory changes and pricing pressures.